GILD : Analysis & Opinions

  1. Markets Falling? Get Your Defense Ready

    April 14, 2014
    The stock market is getting whacked. The question now for many investors is, what to do about it. The first thing to ...
  2. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  3. The 3 Best Growth Stocks To Buy On A Pullback

    February 13, 2014
    Nothing feels worse for investors than missing the boat, and I'm sure there's plenty of regret to go around these ...
  4. These Companies Know The Future Before It Happens

    February 13, 2014
    Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
  5. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  6. Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day

    October 31, 2013
    Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
  7. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  8. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  9. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  10. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  11. Gilead Retained at Neutral - Analyst Blog

    June 25, 2013
    We recently maintained our Neutral recommendation on , Gilead Sciences.
  12. Warning: This Might Be The Most Overvalued Sector In The Market

    June 12, 2013
    When it comes to assessing the outlook for drugmakers, investors really only care about the pipeline of new drugs. After ...
  13. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  14. Priority Review for Gilead Drug - Analyst Blog

    June 10, 2013
    The NDA on Gilead's sofosbuvir will be reviewed on a priority basis by the FDA.
  15. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  16. Gilead Beats Estimates in 4Q - Analyst Blog

    February 5, 2013
    Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option expense) ...
  17. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  18. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  19. Safest Way to Play Biotech - Cook`s Kitchen

    January 25, 2013
    Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the jackpot ...
  20. Gilead's HIV Candidate Advances - Analyst Blog

    January 25, 2013
    Gilead Sciences Inc. (GILD) recently initiated the first of two phase III studies on tenofovir alafenamide (TAF). The study ...
  21. Update on HCV Pipeline from Gilead - Analyst Blog

    January 14, 2013
    Gilead Sciences (GILD) recently provided an update regarding its chronic hepatitis C virus (HCV) pipeline. We note that ...
  22. Actelion Drug Accepted for Review - Analyst Blog

    December 18, 2012
    Switzerland-based Actelion (ALIOF) recently announced that the US Food and Drug Administration (FDA) accepted its New Drug ...
  23. Gilead Plans to Split Stock 2-for-1 - Analyst Blog

    December 11, 2012
    Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, which will ...
  24. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  25. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  26. Gilead Reports Positive HCV Data - Analyst Blog

    November 29, 2012
    Gilead Sciences (GILD) recently presented encouraging top-line data from a phase III study (Positron) which evaluated its ...
  27. Actelion Drug to be Reviewed in EU - Analyst Blog

    November 26, 2012
    The European Medicines Agency (EMA) recently accepted the Marketing Authorisation Application (MAA) filed by Actelion (ALIOF) ...
  28. Gilead Presents Encouraging Data - Analyst Blog

    November 16, 2012
    Gilead Sciences (GILD) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing phase III ...
  29. Gilead and Other Big Movers on the Nasdaq on November 12, 2012

    November 12, 2012
    Currently, the Nasdaq has declined 0.1%, the S&P 500 is unchanged and the Dow has slipped 0.1%. The recent surge in popularity ...
  30. Gilead Among Healthcare's Biggest Movers on November 12, 2012

    November 12, 2012
    The Nasdaq has decreased 0.1%, the S&P 500 has moved little and the Dow is trading down 0.1% so far today. The healthcare ...
  31. Actelion Files NDA for Macitentan - Analyst Blog

    October 29, 2012
    Switzerland-based Actelion (ALIOF) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration ...
  32. Healthcare Stocks, Including Gilead, Making Big Moves on October ...

    October 24, 2012
    So far today, the Nasdaq remains relatively unchanged, the S&P 500 has risen 0.1% and the Dow has climbed 0.3%. The healthcare ...
  33. Actelion Beats; Maintains View - Analyst Blog

    October 19, 2012
    Switzerland-based Actelion (ALIOF) reported third quarter 2012 earnings of $1.17 per American Depository Receipt (ADR), up ...
  34. Arena Pharma Initiates PAH Study - Analyst Blog

    October 15, 2012
    Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being developed ...
  35. Gilead Among Healthcare's Biggest Movers on October 2, 2012

    October 2, 2012
    So far today, the Nasdaq has climbed 0.4%, the S&P 500 is up 0.1% and the Dow is trading down 0.2%. The healthcare sector ...
  36. Gilead and Other Big Movers In Healthcare on October 1, 2012

    October 1, 2012
    It's been a good morning for the market. The Nasdaq has climbed 0.6%; the S&P 500 has increased 0.8%; and the Dow is up 1.1%. ...
  37. Mixed Results from Vertex Studies - Analyst Blog

    September 26, 2012
    Vertex Pharmaceuticals Incorporated (VRTX) and its partner, Alios BioPharma, Inc. recently announced disappointing results ...
  38. Gilead and More Big Movers on the Nasdaq on September 17, 2012

    September 17, 2012
    The market is down this morning. The Nasdaq is down 0.2%; the S&P 500 is trading down 0.2%; and the Dow has slipped 0.2%. ...
  39. Gilead and More Big Movers in Healthcare on September 17, 2012

    September 17, 2012
    The market is having a bad day so far: the Nasdaq has slipped 0.2%; the S&P 500 has declined 0.2%; and the Dow is trading ...
  40. Gilead Among Healthcare's Biggest Movers on September 14, 2012

    September 14, 2012
    The market has been doing well after the morning's trading. The Nasdaq has risen 1.1%; the S&P 500 has increased 0.6%; and ...
  41. Big Movers on the Healthcare Sector Today, Including BMY

    August 2, 2012
    It's been a bad day for the market after the morning's trading. The Nasdaq has fallen 0.4%; the S&P 500 has declined 0.8%; ...
  42. Big Movers on the Healthcare Sector Today, Including GILD

    July 27, 2012
    It's been a good morning for the market. The Nasdaq is up 1.4%; the S&P 500 has risen 1.1%; and the Dow has climbed 0.8%. ...
  43. Earnings Preview: Celgene - Analyst Blog

    July 24, 2012
    Celgene Corporation (CELG) is set to unveil its second quarter 2012 results on July 26, 2012 before the start of trading. ...
  44. FDA Nod for Gilead's Truvada - Analyst Blog

    July 23, 2012
    The US Food and Drug Administration (FDA) recently approved Gilead Sciences, Inc.'s (GILD) once-daily oral Truvada (combination ...
  45. Gilead Seeks FDA Approval - Analyst Blog

    June 28, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that it has filed a marketing application seeking approval for its HIV candidate, ...
  46. EMA Validates Gilead's Drug - Analyst Blog

    June 20, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that its marketing application seeking approval for its HIV candidate elvitegravir ...
  47. The Trend In Rising Cancer Incidences

    June 5, 2012
    As the world continues to modernize and grow, global cancer incidences are expected to increase exponentially and pharmaceutical ...
  48. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  49. Hanesbrands Still A Good Fit

    February 21, 2012
    The long-term appeal of Hanesbrands' business is still there, provided management delivers on its promise to reduce debt.
  50. The Week Ahead: Does This Headline Scare You?

    February 19, 2012
    Bullish magazine headlines have been the death of many a rising market, and in fact a correction is expected, says MoneyShow ...
  51. 3 Stocks You Shouldn't Buy Now

    February 9, 2012
    These three stocks have posted big gains this year, but a proven technical measure shows all are trading at levels where ...
  52. Bristol-Myers Pays Up To Patch A Gap

    January 9, 2012
    Bristol-Myers recently bought Inhibitex, a company leading the way in developing a treatment for Hepatitis C.
  53. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  54. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  55. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  56. 4 Cheap, High-Quality Stocks

    September 23, 2010
    Stocks trading below the S&P 500 P/E average are cheap, but are they a good buy?
  57. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  58. Sanofi Has To Do Something

    July 30, 2010
    Sanofi is priced as though it will never grow again - that's usually a good sign of value.
  59. 5 Stocks Hitting Bottom

    July 29, 2010
    Making bets on stocks that have been driven down too far can be a great way to catch some of the next batch of winners.
  60. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  61. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  62. Forest Labs Shows What Cash Can Do

    May 21, 2010
    When Forest Labs' management realizes that its shares are cheap, the best use of the balance will be to buy back the shares.
  63. Steady Stocks That Keep You In The Race

    May 14, 2010
    In booming markets, anyone can make money. In declining markets, not everyone can prevent significant capital loss. These ...
  64. Will Adaptive Design Change The BioPharma World?

    May 13, 2010
    Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
  65. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  66. 5 Stocks From McDonald's Portfolio

    April 27, 2010
    Take a look inside the profit sharing and savings portfolio McDonald's runs for its employees.
  67. Earnings Winners You Shouldn't Miss

    January 29, 2010
    Plenty of companies have posted disappointing results for last quarter, but a few off-the-radar names have done surprisingly ...
  68. Large Cap Biotech Earnings Preview

    October 16, 2009
    Biotech stocks traditionally fare well through recessions. We'll see if that holds true.
  69. The Best Performing Stocks Of The Decade

    June 9, 2009
    Investors who were able to see past the losses and volatility that some of these companies had in the beginning were amply ...
  70. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide.
  71. Biotech Poised to Disappoint

    April 7, 2009
    The recent wave of big pharma acquisitions does not live up to hype.
  72. 2035 Here We Come

    March 17, 2009
    Target-date retirement funds are all the rage. We provide a model portfolio for those looking to retire in 25 years.
  73. Sequenom Stock Testing Signs Of Life

    January 14, 2009
    Sequenom stock has climbed on the success of a new diagnostic product. Is there any place to go but "down"?
  74. 5 Biotech Stocks To Watch In 2009

    December 30, 2008
    When the market starts to look sickly, can you turn to Biotechs to inject health into your portfolio? Here are five stocks ...
  75. How Much Vigor In Invitrogen?

    October 27, 2008
    Invitrogen is in the right space, but does management have the right plan?
  76. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
  77. Winners and Losers - October 2nd - 6th (MYOG, SWKS, DDSS)

    October 6, 2006
    A look at the winners and losers for the week of October 2nd.
  78. Can Genentech Go Higher?

    April 13, 2006
    A look at the recent quarter of one of the leading biotech companies.
Investing News
  1. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  2. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  3. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  4. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  5. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  6. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
Trading Center